August Dykgers

PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer.

Carsten Denkert, Peter A Fasching, Andreas Schneeweiss, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Single-Cell Atlas of the Tumor and Immune Ecosystem of Human Breast Cancer

Maria Anna Rapsomaniki, Bernd Bodenmiller, Andrea Jacobs, 2019, Cell.

Comparison of MammaPrint and TargetPrint results with clinical parameters in German patients with early stage breast cancer.

A. Glas, T. Dimpfl, H. Gevensleben, 2010, International journal of molecular medicine.